Biotechnology
HistoIndex Extends Access To Its MASH Diagnostic Offering Through New Partnerships In Texas And California
SINGAPORE, April 28, 2026 /PRNewswire/ -- HistoIndex, a pioneer in AI-driven digital pathology solutions for chronic liver disease, has announced the continued expansion of its commercial partnership network in the United States with the addition of two new hepatology and gastroenterology centers...
2026-04-28 15:30
4596
Cordis Launches SELUTION SLR™ PTA Drug-Eluting Balloon (DEB) in Japan
TOKYO, April 28, 2026 /PRNewswire/ -- Cordis, a global leader in interventional cardiovascular technologies, today announces the launch and availability of the SELUTION SLR™ PTA Drug-Eluting Balloon (DEB)1 for use in Japan. SELUTION SLR™ DEB is designed to deliver sirolimus in a controlled, susta...
2026-04-28 09:00
4215
Cellenkos, Inc. Announces FDA Clearance to Initiate Phase 2 Clinical Trial of CK0801 (Allogeneic Cord Blood-Derived Tregs) for Aplastic Anemia
Phase 2 multicenter, open-label study (NCT07499102) will evaluate the safety and clinical efficacy of CK0801 Tregs in transfusion-dependent aplastic anemia. HOUSTON, April 27, 2026 /PRNewswire/ -- Cellenkos®, Inc., a clinical-stage biotechnology company, developing allogeneic, tissue-targeted reg...
2026-04-27 23:19
4651
CONCEPT MEDICAL ANNOUNCES PRELIMINARY 3-YEAR SIRONA DATA AT CHARING CROSS SYMPOSIUM 2026
LONDON, April 27, 2026 /PRNewswire/ -- Concept Medical Inc.
2026-04-27 23:17
3660
WuXi AppTec Delivers Strong Revenue and Profit Growth in Q1 2026
* Total Revenue Reached RMB 12.44 Billion; Revenue from Continuing Operations Up 39.4% YoY * Adjusted Non-IFRS Net Profit Up 71.7% YoY to RMB 4.60 Billion * Backlog for Continuing Operations Up 23.6% YoY to RMB 59.77 Billion SHANGHAI ,April 27, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 60...
2026-04-27 17:03
4204
Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
- Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds <10 IU/mL and HBV DNA rebound infrequent and not associated with clinically significant ALT elevation. These findi...
2026-04-26 19:00
4297
Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE
* For its 30th PCC anniversary, Insilico Medicine nominated ISM0387, the first UAE-based preclinical candidate, jointly announced with the Emirates Drug Establishment (EDE), with the support of local partners including Abu Dhabi Investment Office (ADIO), the Department of Health Abu Dhabi (DoH)...
2026-04-24 21:00
2587
Miracell Demonstrates Cognition Impairment and Brain Function Improvement in Severe Alzheimer's Patients Using 'SMART M-CELL'-Based CD34+ Cell-Rich Autologous Blood Concentrate Therapy
* Study published in SCIE-indexed international journal Molecular Neurobiology * Three intravenous infusions at four-week intervals showed benefits in cognition, brain metabolism, and structural preservation SEOUL, South Korea, April 24, 2026 /PRNewswire/ -- Miracell, a stem cell-focused biotec...
2026-04-24 20:00
3203
HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma
Expanding HanchorBio's data-enabled approach from molecule design to portfolio and market insight TAIPEI and SHANGHAI and SAN FRANCISCO, April 24, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for immun...
2026-04-24 19:30
2552
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival
CHENGDU, China, April 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced the structural completion and key equipment arrival at its microbial commercial manufacturing site in Chengdu, marking a...
2026-04-24 19:03
2677
CMUH and Partners Unveil Breakthrough Targeted Exosome Platform for Non-Invasive Spinal Cord Injury Repair
Developed by China Medical University Hospital, Ever Supreme International Biotechnology Co., Ltd. and SHINE OUT BIO TECHNOLOGY CO., LTD., the platform facilitates intravenous, lesion-targeted delivery of BDNF mRNA and improved motor coordination in preclinical models. TAICHUNG, April 24, 2026 /...
2026-04-24 14:58
2742
Servier completes the acquisition of Day One Biopharmaceuticals
* Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade glioma. * Transaction also includes a strong oncology pipeline of clinical stage assetsin rare cancers with high unmet needs. * Transaction represents total equity ...
2026-04-23 20:30
3557
Fosun Health Strengthens Regional Presence at GlobalHealth Asia-Pacific Forum 2026, Showcasing "China Solution" and Winning Three Major Awards
JAKARTA, Indonesia, April 23, 2026 /PRNewswire/ -- Fosun Health made a prominent debut at the GlobalHealth Asia-Pacific Healthcare Insights & Leadership Forum 2026, held alongside the GlobalHealth Asia-Pacific Awards 2026 at the Grand Hyatt Jakarta, joining a distinguished community of healthcare...
2026-04-23 16:46
3447
Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer
SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces the initiation of a Phase III clinical study of its proprietary Nectin-4-targeting ADC (R&D code: 9MW2821) for the treatment of triple-ne...
2026-04-23 16:22
4204
2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations
SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that two latest clinical study results of its Nectin-4-targeting ADC 9MW2821 in combination with toripalimab for urothelial carcinoma wil...
2026-04-23 15:02
1190
MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
* Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in Australia for adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a).1,2 * De...
2026-04-23 15:00
3133
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics
WUXI, China, April 23, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing facilities in Wuxi – Drug Substance Facility 5 (MFG5), Drug Product Facility 2 (DP2), and Drug P...
2026-04-23 14:14
2925
AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches
SAN DIEGO, April 22, 2026 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and translational research findings in poster sessions at the American Association for Cancer Research (AACR) Annual Meeting, held from April 17 to 22, 2026, in...
2026-04-23 11:37
2470
BioEngine Launches UltraFeed CHO Supplement, Boosting Titers by Up to 48%
SHANGHAI, April 23, 2026 /PRNewswire/ -- Shanghai BioEngine Sci-tech Co., Ltd. announced the launch of UltraFeed, a next-generation fed-batch supplement designed to elevate CHO cell productivity in monoclonal antibody, bispecific, and recombinant protein manufacturing. Across diverse cell lines a...
2026-04-23 09:17
2888
Prestige Biopharma IDC Files Patent for Next-Generation Antibody Delivery Platform 'IDC224'… Driving Innovation in Subcutaneous (SC) Formulations
SEOUL, South Korea, April 23, 2026 /PRNewswire/ -- Prestige Biopharma IDC, the innovative drug research institute of Prestige Biopharma, announced that it has filed a patent for 'IDC224,' a next-generation subcutaneous (SC) delivery platform designed to simultaneously enhance the administration c...
2026-04-23 06:30
3928
Week's Top Stories
Most Reposted
Agoda Makes it Easier for Travelers to See Relevant Photos in Reviews
[Picked up by 313 media titles]
2026-05-06 12:00
Tonik Becomes the First Standalone Digital Bank in the Philippines to Achieve Profitability
[Picked up by 297 media titles]
2026-05-12 10:15
Visa amps up the music as Official Payment Partner for the Asia leg of The Weeknd's 'After Hours Til Dawn' Stadium Tour
[Picked up by 293 media titles]
2026-05-11 16:20
Avnet and HKSTP Invite Global Startups to New AI Hardware Launchpad
[Picked up by 289 media titles]
2026-05-12 10:00Peach Blossoms Celebrates Three Massive Wins - Black Pearl Restaurant Guide 2026, Asia's 50 Best Restaurants 2026 Extended List and Tatler Best 20 Restaurants in Singapore 2026
[Picked up by 283 media titles]
2026-05-12 14:00
Most Read
Amadeus delivers solid Q1 2026 growth, and maintains commercial momentum
2026-05-08 18:30
8081
LightInTheBox to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
2026-05-06 20:00
7461
Massimo Group Launches Sentinel 770 HVAC as Part of Sentinel Product Line Targeting Approximately US$10 Million in 2026 Revenue
2026-05-06 21:20
7325
NYSE Content Update: HawkEye 360 to Start Trading after its $416 Million IPO
2026-05-07 21:35
6846
Pony.ai Labor Day Holiday Robotaxi Paid Orders Surge More Than Sixfold
2026-05-08 20:00
6671